| Literature DB >> 32504600 |
Gino Gerosa1, Lorenzo Longinotti1, Lorenzo Bagozzi1, Augusto D'Onofrio1, Fabio Zanella1, Demetrio Pittarello1, Vincenzo Tarzia2.
Abstract
The AngioVac System has already proved to be effective and safe in the treatment of thrombotic and endocarditic formations concerning the venous district and the tricuspid valve. We describe an innovative use of the AngioVac System to treat a left-sided heart mass. In a high-surgical-risk patient, we used a micro-invasive transapical access and a modified extracorporeal membrane oxygenation circuit to remove the mass from the mitral bioprosthesis without having to replace it. Further experiences are required to confirm the safety of this technique in high-risk patients.Entities:
Mesh:
Year: 2020 PMID: 32504600 DOI: 10.1016/j.athoracsur.2020.04.051
Source DB: PubMed Journal: Ann Thorac Surg ISSN: 0003-4975 Impact factor: 4.330